A Phase 2 interventional study of Varenicline 1mg BID and Placebo in E-cigarette Use, Vaping and Nicotine Dependence, sponsored by Yale University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.
Sponsored by Yale University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Vaping by Yale University — 6 open to participants now, 6 under way, none of them phase 3. Vaping · Yale University.
Among the 22 studies in Vaping by Yale University, this one is the 3rd largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 2, and was the 18th registered.
404 studies on the registry are indexed under Vaping; 97 are open to participants now.
Browse Vaping studies →6 of the 22 studies in Vaping by Yale University are open now, in 1 country. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 21–44 · Healthy volunteers
Yale University · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 12–19 · Healthy volunteers
Yale University · Sites in United States
Ages 12–15 · Healthy volunteers
Yale University · Sites in United States
Ages 14+ · Healthy volunteers
By country, each count listing its studies:
Of the 65 Vaping studies recruiting now, 33 (51%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 5 started in 2025.
This study's planned enrollment of 326 is above the median of 79 across 324 interventional studies indexed under Vaping.
Median enrollment 60 across the 21 interventional studies, 40 across the 1 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
2 of the studies in Vaping by Yale University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07553585Yale UniversitySurvey to Test the Nicotine Concentration and Nicotine Flux Labels for E-cigarettes | 2026-12-15 |
| NCT07398976Yale UniversitySex Differences in E-Cigarette Perception | 2027-04-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Vaping by Yale University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.
Participants will randomly be assigned to 12-weeks of varenicline (titrated to 2mg daily) or matching placebo plus brief cessation advice from a counselor and self-management resources. All participants will also complete research assessments every 3 weeks during treatment and a final follow-up visit at week 26.
The primary objective is to test the efficacy of varenicline vs. placebo on e-cigarette quit rates. We will also evaluate predictors and moderators of outcomes and explore changes in health biomarkers following e-cigarette cessation treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will randomly be assigned to 12-weeks of varenicline (titrated to 2mg daily) plus brief cessation advice with a counselor and self-management resources.
Drug: Varenicline 1mg BID
Participants will randomly be assigned to 12-weeks of matching placebo plus brief cessation advice with a counselor and self-management resources.
Drug: Placebo
12 weeks following the standard titration of 1 mg, twice daily
Matching placebo twice daily
Number of Participants Abstinent From E-cigarette Use at Week 12
7-day point-prevalence e-cigarette abstinence (PPA) at Week 12 defined as no ecigarette use \[and no use of any combusted tobacco product\], not even a puff, biochemically verified by saliva cotinine
Time frame: Week 12
Number of Participants Abstinent From E-cigarette Use at Week 26
7-day point-prevalence e-cigarette abstinence (PPA) at Week 26 defined as no ecigarette use \[and no use of any combusted tobacco product\], not even a puff, biochemically verified by saliva cotinine
Time frame: Week 26
Plan to share: Yes — Data will be shared to an NIH data repository - the NIMH Data Archive
Supporting information: Study protocol, Statistical analysis plan
Access criteria: Access to the data is managed by the NIMH Data Archive
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Jul 2030, 57 months after the start.
Of 16 phase 2 interventional studies under Vaping, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's planned 57 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline